Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>Three contracts have been announced since the Interim report on 6 March and three peer reviewed scientific articles have been published so far this year.</li>
<li>It includes sales from new clients in new therapeutic areas, which not only builds our confidence in the anticipated 31.5% increase in revenue for YE June 2025, but is also positive for FY June 2026.</li>
<li>A contract was reported on 17 March with a brand-new client in the field of Antibody Drug Conjugates (ADCs).</li>
</ul>


Three contracts have been announced since the Interim report on 6 March and three peer reviewed scientific articles have been published so far this year.
It includes sales from new clients in new therapeutic areas, which not only builds our confidence in the anticipated 31.5% increase in revenue for YE June 2025, but is also positive for FY June 2026.
A contract was reported on 17 March with a brand-new client in the field of Antibody Drug Conjugates (ADCs).


<ul>
<li>CleanTech Lithium 9.75p £9.7m (CTL.L) The lithium developer in Chile announced it is collaborating with DuPont Water Solutions, a business unit of DuPont, to test lithium processing technology.</li>
<li>DuPont has developed a new nanofiltration membrane technology for high lithium recovery.</li>
<li>This will be tested in CleanTech Lithium's direct lithium extraction downstream process.</li>
</ul>


CleanTech Lithium 9.75p £9.7m (CTL.L) The lithium developer in Chile announced it is collaborating with DuPont Water Solutions, a business unit of DuPont, to test lithium processing technology.
DuPont has developed a new nanofiltration membrane technology for high lithium recovery.
This will be tested in CleanTech Lithium's direct lithium extraction downstream process.


<ul>
<li>Cirata reported Q125 Trading update for the 3 months to March 2025; its services accelerate datadriven revenue growth by automating data transfer and integration to modern cloud analytics and AI platforms without downtime or disruption.</li>
<li>Revenue of $3m represents the strongest quarter since Q1 2019 and a 330% increase compared to Q124 driven by an enterprise-wide Digital Integration (DI) contract with a leading UK retailer and DI being the core growth driver.</li>
<li>The business mix continued to improve with DI accounting for 80% of bookings and DevOps software the remaining (Q124 DI 57%: DevOps 43%). </li>
</ul>


Cirata reported Q125 Trading update for the 3 months to March 2025; its services accelerate datadriven revenue growth by automating data transfer and integration to modern cloud analytics and AI platforms without downtime or disruption.
Revenue of $3m represents the strongest quarter since Q1 2019 and a 330% increase compared to Q124 driven by an enterprise-wide Digital Integration (DI) contract with a leading UK retailer and DI being the core growth driver.
The business mix continued to improve with DI accounting for 80% of bookings and DevOps software the remaining (Q124 DI 57%: DevOps 43%). 


BATM Advanced Communications / Equity Bottom-Up

<ul>
<li>BATM Advanced Communications 14.7p £64m (BVC.L) The real-time technologies for networks and cyber solutions and medical laboratory systems Company announces its FY results for December 2024.</li>
<li>A marginal increase in total revenue to $117.3m was achieved, with strong growth in the Cyber and Diagnostics divisions offsetting lower revenues in the Networking division.</li>
<li>The Adjusted Profit Before Tax was $3m, down from $5.9m for FY 2023, and Cash and short-term investments were $31.6m (30 June 2024: $32.6m). </li>
</ul>


BATM Advanced Communications 14.7p £64m (BVC.L) The real-time technologies for networks and cyber solutions and medical laboratory systems Company announces its FY results for December 2024.
A marginal increase in total revenue to $117.3m was achieved, with strong growth in the Cyber and Diagnostics divisions offsetting lower revenues in the Networking division.
The Adjusted Profit Before Tax was $3m, down from $5.9m for FY 2023, and Cash and short-term investments were $31.6m (30 June 2024: $32.6m). 


BATM Advanced Communications Ltd - Hybridan Small Cap Feast: 17/03/2025

United Kingdom

Physiomics is a data-driven consultancy that provides Model-Informed Drug Development (MIDD), Biostatistics, Statistical Programming, and Bioinformatics solutions to biopharmaceutical companies and research institutes. The company utilizes its proprietary Virtual Tumour technology platform to optimize the design of cancer clinical trials and predict the effects of treatments. Physiomics was founded in 2001 and is headquartered in Abingdon, United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Physiomics (PYC LN)

Hybridan Research: Physiomics plc

Three contracts have been announced since the Interim report on 6 March and three peer reviewed scientific articles have been published so far this...

Hybridan

Hybridan Small Cap Feast: 17/04/2025

The lithium developer in Chile announced it is collaborating with DuPont Water Solutions, a business unit of DuPont, to test lithium processing...

Hybridan

Hybridan Small Cap Feast: 16/04/2025

The business mix continued to improve with DI accounting for 80% of bookings and DevOps software the remaining (Q124 DI 57%: DevOps 43%).

Hybridan

BATM Advanced Communications Ltd - Hybridan Small Cap Feast: 17/03/2025

The real-time technologies for networks and cyber solutions and medical laboratory systems Company announces its FY results for December 2024.

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)